Vesicular AGR2 splice-variants for non-invasive diagnostics of prostate cancer

Vesicular AGR2 splice-variants for non-invasive diagnostics of prostate cancer - VEDIPRO

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00017155

Enrollment

300

Registered

2019-07-31

Start date

2019-09-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C61

Interventions

Group 1: - Determination of the elevated PSA value by one of the cooperating resident urologists or by urology (Freiburg) - Education about the possibility of study participation - With consent, recor

Eligibility

Sex/Gender

Male

Age

45 Years to 75 Years

Inclusion criteria

Inclusion criteria: PSA > 3 ng/mL

Exclusion criteria

Exclusion criteria: Age > 75 years

Design outcomes

Primary

Measure	Time frame
1) MRI-assisted biopsy (not academic funding, but regular medical insurance) 2) Collection of the histological findings 3) Collection of data from experimental blood and urine examinations, e.g. PSA value Based on collected data, a histological diagnosis of prostate cancer (yes / no) will be determined	—

Secondary

Measure	Time frame
Biomarker panel for detection of prostate cancer. Primary endpoint diagnosis	—

Countries

Germany

Contacts

Public ContactKonrad Wilhelm

Universitätsklinikum Freiburg, Department Chirurgie, Klinik für Urologie

konrad.wilhelm@uniklinik-freiburg.de+4976127028930

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026